Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

aTYR PHARMA (ATYR) Research & Development (2019 - 2025)

aTYR PHARMA's Research & Development history spans 7 years, with the latest figure at $10.9 million for Q4 2025.

  • For Q4 2025, Research & Development fell 10.93% year-over-year to $10.9 million; the TTM value through Dec 2025 reached $60.2 million, up 10.75%, while the annual FY2025 figure was $60.2 million, 10.75% up from the prior year.
  • Research & Development reached $10.9 million in Q4 2025 per ATYR's latest filing, down from $22.1 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $22.1 million in Q3 2025 to a low of $4.5 million in Q1 2021.
  • Average Research & Development over 5 years is $11.1 million, with a median of $10.6 million recorded in 2023.
  • Peak YoY movement for Research & Development: skyrocketed 150.38% in 2022, then dropped 14.45% in 2023.
  • A 5-year view of Research & Development shows it stood at $6.0 million in 2021, then skyrocketed by 150.38% to $14.9 million in 2022, then fell by 14.45% to $12.8 million in 2023, then decreased by 4.13% to $12.2 million in 2024, then decreased by 10.93% to $10.9 million in 2025.
  • Per Business Quant, the three most recent readings for ATYR's Research & Development are $10.9 million (Q4 2025), $22.1 million (Q3 2025), and $15.4 million (Q2 2025).